WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience Introducing ALZET?ew Model 2006 Pump
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, March 16, 2005, 25(11):2803-2810; doi:10.1523/JNEUROSCI.5170-04.2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fryer, J. D.
Right arrow Articles by Holtzman, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fryer, J. D.
Right arrow Articles by Holtzman, D. M.

 Previous Article  |  Next Article 

Neurobiology of Disease
Human Apolipoprotein E4 Alters the Amyloid-{beta} 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model

John D. Fryer,1 Kelly Simmons,1 Maia Parsadanian,1 Kelly R. Bales,4 Steven M. Paul,4,5 Patrick M. Sullivan,6 and David M. Holtzman1,2,3

Departments of 1Neurology and 2Molecular Biology and Pharmacology and 3Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri 63110, 4Neuroscience Discovery Research, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285, 5Departments of Pharmacology, Toxicology, and Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46285, and 6Bryan Alzheimer's Disease Research Center and Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710

Alzheimer's disease (AD) is characterized by the aggregation and deposition of the normally soluble amyloid-{beta} (A{beta}) peptide in the extracellular spaces of the brain as parenchymal plaques and in the walls of cerebral vessels as cerebral amyloid angiopathy (CAA). CAA is a common cause of brain hemorrhage and is found in most patients with AD. As in AD, the {epsilon}4 allele of the apolipoprotein E (apoE) gene (APOE) is a risk factor for CAA. To determine the effect of human apoE on CAA in vivo, we bred human APOE3 and APOE4 "knock-in" mice to a transgenic mouse model (Tg2576) that develops amyloid plaques as well as CAA. The expression of both human apoE isoforms resulted in a delay in A{beta} deposition of several months relative to murine apoE. Tg2576 mice expressing the more fibrillogenic murine apoE develop parenchymal amyloid plaques and CAA by 9 months of age. At 15 months of age, the expression of human apoE4 led to substantial CAA with very few parenchymal plaques, whereas the expression of human apoE3 resulted in almost no CAA or parenchymal plaques. Additionally, young apoE4-expressing mice had an elevated ratio of A{beta} 40:42 in brain extracellular pools and a lower 40:42 ratio in CSF, suggesting that apoE4 results in altered clearance and transport of A{beta} species within different brain compartments. These findings demonstrate that, once A{beta} fibrillogenesis occurs, apoE4 favors the formation of CAA over parenchymal plaques and suggest that molecules or treatments that increase the ratio of A{beta} 40:42 may favor the formation of CAA versus parenchymal plaques.

Key words: Alzheimer's disease; apolipoprotein E; cerebral amyloid angiopathy; amyloid-{beta}; ratio; transgenic models


Received Dec 18, 2004; revised January 25, 2005; accepted January 28, 2005.




This article has been cited by other articles:


Home page
J. Neurosci.Home page
F. Xu, M. P. Vitek, C. A. Colton, M. L. Previti, N. Gharkholonarehe, J. Davis, and W. E. Van Nostrand
Human Apolipoprotein E Redistributes Fibrillar Amyloid Deposition in Tg-SwDI Mice
J. Neurosci., May 14, 2008; 28(20): 5312 - 5320.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
H. Belinson, D. Lev, E. Masliah, and D. M. Michaelson
Activation of the Amyloid Cascade in Apolipoprotein E4 Transgenic Mice Induces Lysosomal Activation and Neurodegeneration Resulting in Marked Cognitive Deficits
J. Neurosci., April 30, 2008; 28(18): 4690 - 4701.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. L. Jankowsky, L. H. Younkin, V. Gonzales, D. J. Fadale, H. H. Slunt, H. A. Lester, S. G. Younkin, and D. R. Borchelt
Rodent Abeta Modulates the Solubility and Distribution of Amyloid Deposits in Transgenic Mice
J. Biol. Chem., August 3, 2007; 282(31): 22707 - 22720.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. Kim, L. Onstead, S. Randle, R. Price, L. Smithson, C. Zwizinski, D. W. Dickson, T. Golde, and E. McGowan
A{beta}40 Inhibits Amyloid Deposition In Vivo
J. Neurosci., January 17, 2007; 27(3): 627 - 633.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. J. Sadowski, J. Pankiewicz, H. Scholtzova, P. D. Mehta, F. Prelli, D. Quartermain, and T. Wisniewski
Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease
PNAS, December 5, 2006; 103(49): 18787 - 18792.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Q. Xu, A. Bernardo, D. Walker, T. Kanegawa, R. W. Mahley, and Y. Huang
Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus.
J. Neurosci., May 10, 2006; 26(19): 4985 - 4994.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
L. Esposito, J. Raber, L. Kekonius, F. Yan, G.-Q. Yu, N. Bien-Ly, J. Puolivali, K. Scearce-Levie, E. Masliah, and L. Mucke
Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice.
J. Neurosci., May 10, 2006; 26(19): 5167 - 5179.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
T. Van Dooren, D. Muyllaert, P. Borghgraef, A. Cresens, H. Devijver, I. Van der Auwera, S. Wera, I. Dewachter, and F. Van Leuven
Neuronal or Glial Expression of Human Apolipoprotein E4 Affects Parenchymal and Vascular Amyloid Pathology Differentially in Different Brain Regions of Double- and Triple-Transgenic Mice
Am. J. Pathol., January 1, 2006; 168(1): 245 - 260.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. E. Wahrle, H. Jiang, M. Parsadanian, R. E. Hartman, K. R. Bales, S. M. Paul, and D. M. Holtzman
Deletion of Abca1 Increases Abeta Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease
J. Biol. Chem., December 30, 2005; 280(52): 43236 - 43242.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Rosand
Editorial Comment--Epistasis Is Coming: Are We Ready?
Stroke, September 1, 2005; 36(9): 1879 - 1880.
[Full Text] [PDF]


Home page
StrokeHome page
D. Woo, R. Kaushal, R. Chakraborty, J. Woo, M. Haverbusch, P. Sekar, B. Kissela, A. Pancioli, E. Jauch, D. Kleindorfer, et al.
Association of Apolipoprotein E4 and Haplotypes of the Apolipoprotein E Gene With Lobar Intracerebral Hemorrhage
Stroke, September 1, 2005; 36(9): 1874 - 1879.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. Malek, L. V. Johnson, B. E. Mace, P. Saloupis, D. E. Schmechel, D. W. Rickman, C. A. Toth, P. M. Sullivan, and C. Bowes Rickman
Apolipoprotein E allele-dependent pathogenesis: A model for age-related retinal degeneration
PNAS, August 16, 2005; 102(33): 11900 - 11905.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. D. Fryer, R. B. DeMattos, L. M. McCormick, M. A. O'Dell, M. L. Spinner, K. R. Bales, S. M. Paul, P. M. Sullivan, M. Parsadanian, G. Bu, et al.
The Low Density Lipoprotein Receptor Regulates the Level of Central Nervous System Human and Murine Apolipoprotein E but Does Not Modify Amyloid Plaque Pathology in PDAPP Mice
J. Biol. Chem., July 8, 2005; 280(27): 25754 - 25759.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-